Vaxart Inc. (VXRT): Price and Financial Metrics


Vaxart Inc. (VXRT): $3.40

0.06 (+1.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VXRT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VXRT POWR Grades


  • VXRT scores best on the Value dimension, with a Value rank ahead of 40.39% of US stocks.
  • VXRT's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • VXRT's current lowest rank is in the Stability metric (where it is better than 3.48% of US stocks).

VXRT Stock Summary

  • Vaxart Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.54% of US listed stocks.
  • With a price/sales ratio of 737.66, Vaxart Inc has a higher such ratio than 99.38% of stocks in our set.
  • Revenue growth over the past 12 months for Vaxart Inc comes in at -77.95%, a number that bests only 1.46% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Vaxart Inc, a group of peers worth examining would be CLDX, LXRX, ADAP, CAPR, and FUSN.
  • VXRT's SEC filings can be seen here. And to visit Vaxart Inc's official web site, go to vaxart.com.

VXRT Valuation Summary

  • VXRT's price/earnings ratio is -20.3; this is 155.62% lower than that of the median Healthcare stock.
  • Over the past 243 months, VXRT's price/earnings ratio has gone down 77.5.
  • VXRT's EV/EBIT ratio has moved down 67.6 over the prior 243 months.

Below are key valuation metrics over time for VXRT.

Stock Date P/S P/B P/E EV/EBIT
VXRT 2021-08-31 887.2 5.5 -20.3 -17.4
VXRT 2021-08-30 875.3 5.4 -20.1 -17.2
VXRT 2021-08-27 897.1 5.6 -20.6 -17.7
VXRT 2021-08-26 893.1 5.5 -20.5 -17.6
VXRT 2021-08-25 913.0 5.7 -20.9 -18.0
VXRT 2021-08-24 893.1 5.5 -20.5 -17.6

VXRT Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 51.3%.
  • Its 2 year cash and equivalents growth rate is now at 70.67%.
  • Its 4 year cash and equivalents growth rate is now at -2.42%.
VXRT's revenue has moved down $8,008,000 over the prior 52 months.

The table below shows VXRT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.892 -59.832 -70.47
2021-09-30 1.174 -54.784 -63.567
2021-06-30 1.239 -49.772 -54.069
2021-03-31 1.65 -37.134 -46.93
2020-12-31 4.046 -23.75 -32.22
2020-09-30 7.606 -16.776 -24.768

VXRT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VXRT has a Quality Grade of D, ranking ahead of 8.43% of graded US stocks.
  • VXRT's asset turnover comes in at 0.007 -- ranking 401st of 680 Pharmaceutical Products stocks.
  • ABEO, BCDA, and PCRX are the stocks whose asset turnover ratios are most correlated with VXRT.

The table below shows VXRT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 1 -2.885
2021-03-31 0.011 1 -7.113
2020-12-31 0.038 1 81.691
2020-09-30 0.099 1 12.466
2020-06-30 0.159 1 19.968
2020-03-31 0.174 1 -81.273

VXRT Price Target

For more insight on analysts targets of VXRT, see our VXRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

VXRT Stock Price Chart Interactive Chart >

Price chart for VXRT

VXRT Price/Volume Stats

Current price $3.40 52-week high $10.33
Prev. close $3.34 52-week low $2.49
Day low $3.31 Volume 1,761,754
Day high $3.50 Avg. volume 2,603,649
50-day MA $4.19 Dividend yield N/A
200-day MA $6.01 Market Cap 429.78M

Vaxart Inc. (VXRT) Company Bio


Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.


VXRT Latest News Stream


Event/Time News Detail
Loading, please wait...

VXRT Latest Social Stream


Loading social stream, please wait...

View Full VXRT Social Stream

Latest VXRT News From Around the Web

Below are the latest news stories about Vaxart Inc that investors may wish to consider to help them evaluate VXRT as an investment opportunity.

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 25, 2022

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the fourth quarter and full year 2021, reporting forward mom

Yahoo | February 24, 2022

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- A new study p

Yahoo | February 24, 2022

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

Right now, I'm thinking of a biotech company with game-changing vaccine technology and a company whose successes are tied to the cryptocurrency market. The coronavirus pandemic put Vaxart's (NASDAQ: VXRT) name on the map. Vaxart's candidate still is in phase 2 trials.

Yahoo | February 23, 2022

Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Read More 'VXRT' Stories Here

VXRT Price Returns

1-mo -5.82%
3-mo -34.74%
6-mo -54.55%
1-year -47.85%
3-year 400.00%
5-year -36.92%
YTD -45.77%
2021 9.81%
2020 1,529.10%
2019 -81.36%
2018 -70.02%
2017 -53.66%

Continue Researching VXRT

Here are a few links from around the web to help you further your research on Vaxart Inc's stock as an investment opportunity:

Vaxart Inc (VXRT) Stock Price | Nasdaq
Vaxart Inc (VXRT) Stock Quote, History and News - Yahoo Finance
Vaxart Inc (VXRT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9016 seconds.